The association between dermatomyositis (DM) and various types of malignancies has been reported in several studies, with an estimated frequency of about 20-25%. Cancer may appear before the onset of DM, concurrently with DM or after its onset. In the present report, the occurrence of typical DM in concomitance with development of skin metastases from previously treated breast cancer is described, suggesting the role of DM as paraneoplastic marker not only in association with the primary tumor but also in case of cutaneous involvement by cancer.
Introduction
Dermatomyositis (DM) is a rare disorder of the connective tissue, clinically characterized by weakness of proximal muscles and peculiar cutaneous involvement. DM can be exclusively or predominantly cutaneous, or also aVect various organs: lungs, heart, joints, gastrointestinal system. Peaks of incidence occur in children and middle-aged adults: in the latter, DM is frequently a paraneoplastic syndrome, and its course is closely correlated with that of the underlying malignancy [1, 2] .
We report a typical case of DM occurring in a patient aVected by extensive cutaneous recurrence of breast cancer and skin metastases, with simultaneous onset and parallel course of the diseases. To the best of our knowledge this association has not been previously reported.
Case report
A 74-year-old woman was diagnosed in November 2005 with stage IIIC inWltrating ductal carcinoma of her right breast. She underwent partial mastectomy and was treated postoperatively with four cycles of docetaxel, followed by loco-regional radiotherapy. This led to clinical remission, with no residual lesions visible in computed tomography scan; serum level of cancer antigen-15.3 was 19.7 U/ml. She was therefore put on therapy with anastrozole.
In December 2006, she was referred to our outpatients service with erythematous lesions appearing recently on the upper part of her body, associated with progressively worsening general asthenia. Clinical examination showed heliotrope rash with periorbital edema, as well as erythematous and poikilodermatous macules with slight scales, involving cheeks, upper chest (Fig. 1) , and the extensor surface of both arms. Erythematous, inWltrating, indurated plaques in the axillary region, close to the site of the previous partial mastectomy (Fig. 1b) , and multiple nodules in the back (Fig. 1c ) and abdomen were also observed. Breast ultrasonography showed multiple lesions in the right breast; Wne needle aspiration followed by cytologic examination was positive for tumoral cells, in agreement with the diagnosis of extensive cutaneous metastatic breast cancer.
Neurologic evaluation showed diVuse hyposthenia, with major involvement of proximal muscles; a myogenic pattern in the deltoid muscle was observed on electromyography. Laboratory exams revealed increased levels of antinuclear antibodies (titer 1:160), SSA-Ro antibodies (3,000 IU/ml), creatin phosphokinase (300 U/L), erythrocyte sedimentation rate (49 mm/h). Nailfold capillaroscopy showed rarefaction of capillaries, with loss of the normal distribution pattern; moreover, some megacapillaries were present. Muscle biopsy revealed a predominantly perimysial and perivascular lymphocytic inWltrate, obliteration of multiple blood vessels, some areas of muscle infarction. Skin biopsy showed atrophic epidermis, vacuolar degeneration of the basal layer, dermal edema, caused by mucin, and mild perivascular inWltration of lymphocytes.
On the above basis, we diagnosed DM, and the patient was treated with oral prednisone 1 mg/kg per day, with adequate tapering, and immunoglobulins (2 g/kg). Hormonal treatment was stopped and antiblastic therapy with gemcitabine and liposomal doxorubicin (5 cycles) was started; the therapy was well tolerated and achieved a moderate improvement of the loco-regional relapse of the tumor and a parallel improvement of the cutaneous and muscular involvement.
Discussion
Dermatomyositis is well known as a paraneoplastic syndrome, although an exact estimation of its association with internal malignancies is not possible, because of the heterogeneity of literature data [3] [4] [5] [6] . Several Scandinavian researchers, however, have evaluated the frequency of malignancy in subjects aVected by DM and in the general population, and have observed that the slight increase in cancer frequency in DM patients is not highly signiWcant, and could be explained by a more aggressive cancer search [7] . Various types of malignancies have been found in association with DM: the most common are carcinomas of the lung, breast, ovary, stomach, but many others have been reported in literature. Their rate of incidence in patients with DM is similar to that observed in the general population [3] [4] [5] [6] .
The pathogenic link between DM and tumors is still conjectural. DM has to be considered as an autoimmune disease in which both genetic and coincidental factors (such as neoplastic antigens, hormones or hormone precursors, fetal proteins, antibodies, cytokines) seem to play a determinant pathogenic role, through disregulation of the immune system and production of antibodies and cytotoxic lymphocytes against autoantigens which are similar to tumor antigens. The production of large amounts of the above biologically active substances may cause tissue damage through deposition of immune complexes and/or recognition/modiWcation of muscular and cutaneous antigens, which can subsequently activate autoreactive T-lymphocytes [5, 8] . Many lines of evidence have suggested that tumor necrosis factor alpha (TNF-alpha) plays a pivotal role in the pathogenesis of DM [9] : this is conWrmed by the good results obtained using diVerent regimens of anti-TNF agents (etanercept, inXiximab or rituximab) for the treatment of DM [10, 11] . It is well known that ovarian or peripherallyderived estrogens may induce production of proinXammatory cytokines (i.e., TNF-alpha) by skin or immune cells [12, 13] . Recently, Sereda et al. [13] described the case of two young women with breast cancer, whose DM-associated skin manifestations signiWcantly improved while taking antiestrogens such as docetaxel (a selective estrogen receptor modulator) and anastrazole (an aromatase inhibitor), probably because of inhibition of the TNF-alpha synthesis.
In our patient, no changes in DM-related rash were observed during antiestrogen treatment, suggesting that diVerent immunologic and non-immunologic pathways may be involved in the pathogenesis of DM. Studies with larger groups of patients and longer observation periods are necessary to better clarify the relationship between DM and malignancies, autoimmunity and hormonal status (i.e., estrogens), as well as the risks and beneWts associated with therapy.
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